A phase I/II open label study of IPH1101 (with low dose of interleukin-2 [IL-2]) in combination with rituximab re-treatment in patients with Follicular Lymphoma The primary objective of this study is to assess the clinical efficacy of IPH1101 (with low-dose IL 2, as aldesleukin), administered in combination with a standard course of rituximab, in patients wit...

• Country None
• organs None
• Specialty None